Langar Global HealthTech ETF

Wall Street Zen Upgrades Intuitive Surgical's Rating to Buy

Wilmington Savings Fund Association Reduces Intuitive Surgical Holdings

Emergency Care Holdings Launches Heartstream as an Independent Company

Intuitive Surgical reports Q4 earnings

Veeva Systems CEO Reports Sale of Company's Common Stock

UBS downgrades GE HealthCare stock rating to sell

Expected Analysis of Dekang Medical's Q4 2025 Financial Report

GE Healthcare's Q4 2025 Earnings Forecast Analysis

Intuitive Surgical to Release FY2025 Q4 Earnings on January 22 After-Market EST, Forecast Revenue USD 2.724 B, EPS USD 1.9637

Brandon Wazquez Maintains Intuitive Surgical 'Buy' Rating

Philips' Emergency Care Business Transformed into ECH Platform Company

Intuitive Surgical Reports Q4 2025 Revenue Growth of 19%, Exceeding Expectations

Intuitive Surgical Expects Q4 2025 Revenue of $2.87B and FY 2025 Revenue of $10.06B

PKO Investment Management Reduces Holdings in IQVIA

Exencial Wealth Advisors LLC Increases Holdings in IQVIA Holdings Inc.

Veeva Systems showcases industry cloud strategy and AI innovation at JPM 2026 Healthcare Conference

Insulet Corporation showcases Auto-Injector Delivery System

Bernstein Reiterates Buy Rating on Intuitive Surgical

Goldman Sachs Issues a Sell Rating on Veeva Systems

Key Points to Note Before IQVIA's Earnings Release

Venus Concept

Jeffs Brands

Jaguar Health

TNL Mediagene

Baiya

Locafy

ImmunityBio

Painreform

Bristol-Myers Squibb Company

NeoVolta

ISRG

LB filings

Intuitive Surgical

Intuitive Surgical | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 2.87 B

Intuitive Surgical Inc. reported a 21% revenue growth for 2025, with preliminary full-year revenue reaching approximately $10.06 billion. The fourth quarter revenue was about $2.87 billion, a 19% increase from the previous year. Worldwide procedures using the da Vinci and Ion platforms grew by 18%, with da Vinci procedures up 17% and Ion procedures up 44%. The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems. A conference call to discuss full financial results is scheduled for January 22, 2026.

Reuters

Intuitive Surgical Reports 21% Revenue Growth for 2025

VEEV

Veeva Systems Inc. presented its industry cloud strategy and AI innovations for life sciences at the J.P. Morgan 2026 Healthcare Conference. The company emphasized its cloud solutions for development, quality, commercial, and data management needs. Veeva highlighted its structural advantages and discussed industry changes, including the rise of artificial intelligence and a more connected ecosystem.

Veeva Systems -CL

Veeva Systems unveils industry cloud strategy and AI innovations for life sciences in new presentation

PODD

Insulet Corporation showcased its leadership in diabetes management at the J.P. Morgan 44th Annual Healthcare Conference. The company highlighted its FDA-cleared Automated Insulin Delivery (AID) system, which is the most prescribed in the U.S. Insulet anticipates approximately $2.7 billion in revenue for 2025 and has over 600,000 active customers globally. The company has contributed to two-thirds of the AID market growth from 2020 to 2025, achieving a 26% CAGR and nearing a 50% share of global revenue in this segment.

Insulet

Insulet Corporation highlights diabetes management leadership and market growth in new investor presentation

ResMed Inc. showcased its leadership in connected health at the JPM Healthcare Conference, reporting $5.3 billion in revenue for the last twelve months as of September 30, 2025. The company operates in over 140 countries with a workforce of 10,000. It highlighted strong operating margins, a net cash position of $715 million, and a 31% increase in free cash flow. ResMed emphasized growth opportunities in underpenetrated markets for sleep apnea, advances in digital health, and ongoing investments in innovation to improve patient care.

Resmed

ResMed Inc. highlights global leadership in connected health and growth strategy in new investor presentation

DXCM

Dexcom, a glucose monitoring company, reported preliminary Q4 revenue growth of 13%, surpassing analyst expectations. The growth is attributed to the launch of its G7 15 Day sensor technology. For fiscal 2025, revenue is projected to increase by 16% year-over-year, with an anticipated revenue of $5.16 - $5.25 billion for 2026, reflecting an 11-13% growth. The company also noted a strong international revenue increase of 18% in Q4. Analysts maintain a "buy" rating on Dexcom shares, with a median 12-month price target of $84.71, indicating a potential upside from its current trading price.

DexCom

Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch

DexCom | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 1.26 B

Deltec Asset Management LLC has acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG), purchasing 2,000 shares valued at approximately $894,000. Other institutional investors, including Trilogy Capital Inc. and Forum Financial Management LP, have also increased their holdings in the company. Recent insider sales include significant transactions by SVP Mark Brosius and insider Gary S. Guthart. Analysts have raised price targets for ISRG, with HSBC setting a new target of $644.00 and a consensus rating of "Moderate Buy" with an average target price of $622.17.

Market Beat

Deltec Asset Management LLC Buys New Stake in Intuitive Surgical, Inc. $ISRG

Veeva Systems (NYSE: VEEV) has announced a new Environmental Monitoring (EM) solution aimed at enhancing quality control (QC) in manufacturing. This cloud-based application integrates with Veeva LIMS, allowing labs and production sites to plan, collect, and analyze environmental samples to ensure compliance with GMP and internal sterility standards. The solution is part of Veeva Quality Cloud and is expected to be available in December 2026. Veeva aims to modernize quality and manufacturing processes by eliminating outdated technologies and streamlining batch release procedures.

prnewswire

23:26 ET
			
			
			
				
					Veeva stellt eine Umweltüberwachungslösung zur Modernisierung der Qualitätskontrolle in der Fertigung vor

Intuitive Surgical (NASDAQ:ISRG) has delivered an average annual return of 20.44% over the past 20 years, outperforming the market by 11.68%. With a current market capitalization of $200.64 billion, a $100 investment in ISRG stock two decades ago would now be worth $4,041.87, highlighting the significant impact of compounded returns on investment growth.

benzinga_article

$100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today

GAM Holding AG reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 27.5% in Q3, now holding 16,350 shares valued at $7.31 million. Other institutional investors also adjusted their positions, with Brighton Jones LLC increasing its stake by 24.9%. Insider sales included significant transactions by SVP Mark Brosius and EVP Henry L. Charlton. Intuitive Surgical's stock opened at $561.98, with a market cap of $201.46 billion and a P/E ratio of 74.34. The company reported strong earnings, exceeding estimates with $2.40 EPS and $2.51 billion in revenue for the last quarter.

Intuitive Surgical, Inc. $ISRG Shares Sold by GAM Holding AG

GEHC

Medtech stocks are ending 2025 with a clear divide: Becton Dickinson, Zimmer Biomet, Baxter, and Stryker are facing yearly losses, while Boston Scientific, Medtronic, Johnson & Johnson, Abbott, Edwards Lifesciences, and GE HealthCare are on track for gains. Zimmer Biomet and Baxter have seen significant declines due to profit warnings and disruptions. In contrast, JNJ has surged over 43%, reaching a record high. Analysts predict a more stable 2026 for MedTech, anticipating strong growth as tariffs and policy risks ease.

Zimmer Biomet

Boston Scientific

Edwards Lifesciences

GE HealthCare Tech

BUZZ-Medtech: Clear split between gainers and losers in 2025

Insulet Corporation has remediated a previously disclosed material weakness in its IT controls affecting financial reporting outside North America. No reportable events or disagreements occurred with its former auditor, Grant Thornton LLP, during fiscal years 2023-2024 and up to December 15, 2025. This information was published via EDGAR by Insulet Corporation.

Insulet Discloses Remediated IT Control Weakness in Financial Reporting

TOST

On CNBC's 'Halftime Report Final Trades,' Stephanie Link highlighted Dick's Sporting Goods, noting its 11% drop from highs and strong Q3 results. Bill Baruch chose Intuitive Surgical, supported by Truist Securities' Buy rating and raised price target. Joshua Brown picked Toast, backed by JPMorgan's upgrade to Overweight. Intuitive Surgical shares rose 0.9%, Dick's Sporting gained 1%, and Toast shares increased 3.2%.

Toast

Dick's Sporting, Intuitive Surgical And A Tech Stock On CNBC's 'Final Trades'

Vaso Corporation Extends Sales Agreement with GE HealthCare Through 2030